J Hartmann1, J Wölfelschneider1, C Stache2, R Buslei2, A Derer1, M Schwarz3, T Bäuerle3, R Fietkau1, U S Gaipl1, C Bert4, A Hölsken2, B Frey1. 1. Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany. 2. Institute of Neuropathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. 3. Institute of Radiology, Preclinical Imaging Platform Erlangen (PIPE), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. 4. Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany. christoph.bert@uk-erlangen.de.
Abstract
BACKGROUND AND PURPOSE: Small animal irradiation systems were developed for preclinical evaluation of tumor therapy closely resembling the clinical situation. Mostly only clinical LINACs are available, so protocols for small animal partial body irradiation using a conventional clinical system are essential. This study defines a protocol for conformal brain tumor irradiations in mice. MATERIALS AND METHODS: CT and MRI images were used to demarcate the target volume and organs at risk. Three 6 MV photon beams were planned for a total dose of 10 fractions of 1.8 Gy. The mouse position in a dedicated applicator was verified by an X‑ray patient positioning system before each irradiation. Dosimetric verifications (using ionization chambers and films) were performed. Irradiation-induced DNA damage was analyzed to verify the treatment effects on the cellular level. RESULTS: The defined treatment protocol and the applied fractionation scheme were feasible. The in-house developed applicator was suitable for individual positioning at submillimeter accuracy of anesthetized mice during irradiation, altogether performed in less than 10 min. All mice tolerated the treatment well. Measured dose values perfectly matched the nominal values from treatment planning. Cellular response was restricted to the target volume. CONCLUSION: Clinical LINAC-based irradiations of mice offer the potential to treat orthotopic tumors conformably. Especially with respect to lateral penumbra, dedicated small animal irradiation systems exceed the clinical LINAC solution.
BACKGROUND AND PURPOSE: Small animal irradiation systems were developed for preclinical evaluation of tumor therapy closely resembling the clinical situation. Mostly only clinical LINACs are available, so protocols for small animal partial body irradiation using a conventional clinical system are essential. This study defines a protocol for conformal brain tumor irradiations in mice. MATERIALS AND METHODS: CT and MRI images were used to demarcate the target volume and organs at risk. Three 6 MV photon beams were planned for a total dose of 10 fractions of 1.8 Gy. The mouse position in a dedicated applicator was verified by an X‑ray patient positioning system before each irradiation. Dosimetric verifications (using ionization chambers and films) were performed. Irradiation-induced DNA damage was analyzed to verify the treatment effects on the cellular level. RESULTS: The defined treatment protocol and the applied fractionation scheme were feasible. The in-house developed applicator was suitable for individual positioning at submillimeter accuracy of anesthetized mice during irradiation, altogether performed in less than 10 min. All mice tolerated the treatment well. Measured dose values perfectly matched the nominal values from treatment planning. Cellular response was restricted to the target volume. CONCLUSION: Clinical LINAC-based irradiations of mice offer the potential to treat orthotopic tumors conformably. Especially with respect to lateral penumbra, dedicated small animal irradiation systems exceed the clinical LINAC solution.
Entities:
Keywords:
Craniopharyngioma; Mouse irradiation; Orthotopic; Small field dosimetry; Xenograft
Authors: K H Song; R Pidikiti; S Stojadinovic; M Speiser; S Seliounine; D Saha; T D Solberg Journal: Phys Med Biol Date: 2010-11-16 Impact factor: 3.609
Authors: Christina Stache; Annett Hölsken; Sven-Martin Schlaffer; Andreas Hess; Markus Metzler; Benjamin Frey; Rudolf Fahlbusch; Jörg Flitsch; Michael Buchfelder; Rolf Buslei Journal: Brain Pathol Date: 2014-05-19 Impact factor: 6.508
Authors: John Wong; Elwood Armour; Peter Kazanzides; Iulian Iordachita; Erik Tryggestad; Hua Deng; Mohammad Matinfar; Christopher Kennedy; Zejian Liu; Timothy Chan; Owen Gray; Frank Verhaegen; Todd McNutt; Eric Ford; Theodore L DeWeese Journal: Int J Radiat Oncol Biol Phys Date: 2008-08-01 Impact factor: 7.038
Authors: Annett Hölsken; Marc Schwarz; Clarissa Gillmann; Christina Pfister; Michael Uder; Arnd Doerfler; Michael Buchfelder; Sven Schlaffer; Rudolf Fahlbusch; Rolf Buslei; Tobias Bäuerle Journal: PLoS One Date: 2018-05-24 Impact factor: 3.240
Authors: Manuel Valiente; Amanda E D Van Swearingen; Carey K Anders; Amos Bairoch; Adrienne Boire; Paula D Bos; Diana M Cittelly; Neta Erez; Gino B Ferraro; Dai Fukumura; Brunilde Gril; Meenhard Herlyn; Sheri L Holmen; Rakesh K Jain; Johanna A Joyce; Mihaela Lorger; Joan Massague; Josh Neman; Nicola R Sibson; Patricia S Steeg; Frits Thorsen; Leonie S Young; Damir Varešlija; Adina Vultur; Frances Weis-Garcia; Frank Winkler Journal: Cancer Res Date: 2020-07-08 Impact factor: 12.701
Authors: Lorenzo Galluzzi; Ilio Vitale; Sarah Warren; Sandy Adjemian; Patrizia Agostinis; Aitziber Buqué Martinez; Timothy A Chan; George Coukos; Sandra Demaria; Eric Deutsch; Dobrin Draganov; Richard L Edelson; Silvia C Formenti; Jitka Fucikova; Lucia Gabriele; Udo S Gaipl; Sofia R Gameiro; Abhishek D Garg; Encouse Golden; Jian Han; Kevin J Harrington; Akseli Hemminki; James W Hodge; Dewan Md Sakib Hossain; Tim Illidge; Michael Karin; Howard L Kaufman; Oliver Kepp; Guido Kroemer; Juan Jose Lasarte; Sherene Loi; Michael T Lotze; Gwenola Manic; Taha Merghoub; Alan A Melcher; Karen L Mossman; Felipe Prosper; Øystein Rekdal; Maria Rescigno; Chiara Riganti; Antonella Sistigu; Mark J Smyth; Radek Spisek; John Stagg; Bryan E Strauss; Daolin Tang; Kazuki Tatsuno; Stefaan W van Gool; Peter Vandenabeele; Takahiro Yamazaki; Dmitriy Zamarin; Laurence Zitvogel; Alessandra Cesano; Francesco M Marincola Journal: J Immunother Cancer Date: 2020-03 Impact factor: 13.751